Prostate-Specific Membrane Antigen (PSMA)-Targeted ...
PSMA-PET imaging, particularly with 68Ga-PSMA-11, is effective for detecting prostate cancer at low PSA levels. PSMA-targeted radionuclide therapy (TRT) using 131I-MIP-1095 and 177Lu-PSMA-617 shows promise in treating metastatic castration-resistant prostate cancer (mCRPC), with significant PSA declines observed. However, challenges include toxicity and the need for personalized dosing. Ongoing trials aim to optimize dosing and compare 177Lu-PSMA-617 with standard treatments, with VISION and TheraP studies highlighting its potential benefits over chemotherapy.
Related Clinical Trials
Reference News
PSMA-PET imaging, particularly with 68Ga-PSMA-11, is effective for detecting prostate cancer at low PSA levels. PSMA-targeted radionuclide therapy (TRT) using 131I-MIP-1095 and 177Lu-PSMA-617 shows promise in treating metastatic castration-resistant prostate cancer (mCRPC), with significant PSA declines observed. However, challenges include toxicity and the need for personalized dosing. Ongoing trials aim to optimize dosing and compare 177Lu-PSMA-617 with standard treatments, with VISION and TheraP studies highlighting its potential benefits over chemotherapy.